Overview

Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety and activity of SGN-40 in a weekly dosage schedule as a single agent.
Phase:
Phase 1
Details
Lead Sponsor:
Seagen Inc.
Seattle Genetics, Inc.
Collaborator:
Genentech, Inc.
Treatments:
Antibodies
Dacetuzumab